Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KDM6A mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

KDM6A amplification (1)

KDM6A amplification (1)

›

KDM6A mutation	Gastric Cancer	KDM6A mutation	Gastric Cancer	5-fluorouracil Sensitive: B - Late Trials 5-fluorouracil Sensitive : B	5-fluorouracil Sensitive: B - Late Trials 5-fluorouracil Sensitive : B
KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
KDM6A mutation	Acute Myelogenous Leukemia	KDM6A mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4
KDM6A mutation	Renal Cell Carcinoma	KDM6A mutation	Renal Cell Carcinoma	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D